-
公开(公告)号：US11795164B2
公开(公告)日：2023-10-24
申请号：US17819602
申请日：2022-08-12
发明人： Ilona Gutcher , Norbert Schmees , Lars Röse , Benjamin Bader , Christina Kober , Rafael Carretero , Detlef Stöckigt , Horst Irlbacher , Michael Platten
IPC分类号： C07D417/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , A61P35/00
CPC分类号： C07D417/04 , A61P35/00 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04
摘要： The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (1):
in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.-
公开(公告)号：US11161825B2
公开(公告)日：2021-11-02
申请号：US16638683
申请日：2018-08-09
发明人： Jörg Weiske , Carlo Stresemann , Stefan Nikolaus Gradl , Ulrike Röhn , Clara Christ , Holger Steuber , Manfred Husemann , Norbert Schmees , Kai Thede , Stephan Siegel , Antonius Ter Laak
IPC分类号： C07D243/12 , C07D401/06 , C07D403/06 , C07D409/06 , C07D413/06
摘要： The present invention covers 4-oxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine-7-carboxamide compounds of general formula (I): in which R1, R2a, R2b, R2c, R3a, R3b, R4a, R4b, R5 and X are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer, as a sole agent or in combination with other active ingredients.
-
公开(公告)号：US11998539B2
公开(公告)日：2024-06-04
申请号：US18072490
申请日：2022-11-30
发明人： Norbert Schmees , Lars Wortmann , Dennis Kirchhoff , Thi Thanh Uyen Nguyen , Nicolas Werbeck , Ulf Bömer , Kirstin Petersen , Christina Kober , Christian Lechner , Dirk Kosemund , Rienk Offringa , Mareike Grees , Benjamin Bader
IPC分类号： A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/55 , A61K45/06 , A61P35/00 , A61P37/04 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
CPC分类号： A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/55 , A61K45/06 , A61P35/00 , A61P37/04 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14
摘要： The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.
-
公开(公告)号：US11524944B2
公开(公告)日：2022-12-13
申请号：US16765780
申请日：2018-11-16
发明人： Julien Lefranc , Norbert Schmees , Ulrike Röhn , Ludwig Zorn , Judith Günther , Ilona Gutcher , Lars Röse , Benjamin Bader , Detlef Stöckigt , Michael Platten
IPC分类号： C07D239/28 , A61P35/04 , C07D405/12 , A61K45/06
摘要： The present invention covers 2-phenylpyrimidine-4-carboxamide compounds of general formula (I): (I) 5 in which X, Y, Z, R1, R2, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
-
公开(公告)号：US11304946B2
公开(公告)日：2022-04-19
申请号：US16765778
申请日：2018-11-16
发明人： Julien Lefranc , Norbert Schmees , Ulrike Röhn , Ludwig Zorn , Judith Günther , Ilona Gutcher , Lars Röse , Benjamin Bader , Detlef Stöckigt , Michael Platten
IPC分类号： C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , A61K31/506
摘要： The present invention covers 2-hetarylpyrimidine-4-carboxamide compounds of general formula (I): in which X, Y, Z, R1, R2 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
-
公开(公告)号：US11040035B2
公开(公告)日：2021-06-22
申请号：US16303539
申请日：2017-05-23
发明人： Norbert Schmees , Ilona Gutcher , Horst Irlbacher , Benjamin Bader , Na Zhao , Michael Platten , Ulrike Röhn , Ludwig Zorn , Lars Röse , Detlef Stöckigt
IPC分类号： C07D237/14 , C07D237/20 , C07D401/10 , C07D405/12 , A61K31/501 , A61P35/00 , A61K31/50 , A61K45/06 , C07D237/24 , C07D403/12
摘要： The present invention covers 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamide compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with 10 dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
-
公开(公告)号：US09663523B2
公开(公告)日：2017-05-30
申请号：US14432158
申请日：2013-09-25
申请人： BAYER PHARMA AKTIENGESELLSCHAFT , Helga Künzer , Klara Muno , Erich Künzer , Martin Künzer , Christel Bernsdorf
发明人： Norbert Schmees , Joachim Kuhnke , Bernard Haendler , Roland Neuhaus , Pascale Lejeune , Stephan Siegel , Martin Krüger , Amaury Ernesto Fernandez-Montalvan , Hermann Künzer , Daniel Gallenkamp
IPC分类号： A61K31/55 , C07D487/04 , C07D519/00
CPC分类号： C07D487/04 , A61K31/55 , C07D519/00
摘要： The present invention relates to BET-protein-inhibitory, in particular BRD4-inhibitory 5-aryltriazoloazepines of the general formula (I) in which R1, R2, R3 and R4 have the meanings given for the general formula (I), to pharmaceutical compositions comprising the compounds according to the invention, and to the prophylactic and therapeutic use thereof for hyperproliferative disorders, especially for neoplastic disorders. The present invention further relates to the use of BET protein inhibitors in viral infections, in neurodegenerative disorders, in inflammatory diseases, in atherosclerotic disorders and in male fertility control.
-
8.发明申请INTRAUTERINE APPLICATION OF 18-METHYL-15SS,16SS-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONE SYSTEMS, INTRAUTERINE SYSTEMS CONTAINING 18-METHYL-15SS,16SS-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONE, AS WELL AS THE USE THEREOF IN CONTRACEPTION AND GYNAECOLOGICAL THERAPY 审中-公开18-甲基-15SS，16SS-甲基-19-异-20-螺环-4-EN-3-ONE系统的内含子应用，含有18-甲基-15SS，16SS-甲基-19-非 - 20-螺旋体的内含子系统 -4-EN-3-ONE，以及其在合同和妇科治疗中的应用公开(公告)号：US20150065472A1
公开(公告)日：2015-03-05
申请号：US14396736
申请日：2013-04-19
发明人： Norbert Schmees , Lars Röse , Tuula Valo , Katja Prelle , Reinhard Nubbemeyer , Henriikka Korolainen , Harri Jukarainen
CPC分类号： A61K31/58 , A61K9/0039
摘要： The present invention describes intrauterine use of 18-methyl-15β,16β-methylene-19-nor-20-spirox-4-en-3-ones of the general formula (1) in contraception and gynaecological treatment, and an intrauterine system comprising compounds of formula 1.
摘要翻译： 本发明描述了在避孕和妇科治疗中宫颈内使用通式（1）的18-甲基-15β，16β-亚甲基-19-去甲螺环-4-烯-3-酮和子宫内 系统包含式1的化合物。
-
公开(公告)号：US20150203483A1
公开(公告)日：2015-07-23
申请号：US14421994
申请日：2013-08-13
发明人： Stephan Siegel , Stefan Bäurle , Arwed Cleve , Bernard Haendler , Amaury Ernesto Fernandiez-Montalvan , Ursula Mönning , Sabine Krause , Pascale Lejeune , Norbert Schmees , Matthias Busemann , Simon Holton , Joachim Kuhnke
IPC分类号： C07D417/10 , A61K31/551 , C07D413/10 , C07D403/10 , C07D413/14 , C07D409/10 , C07D401/04 , C07D401/14 , A61K31/5513 , C07D401/12 , C07D243/02 , C07D401/10
CPC分类号： C07D417/10 , A61K31/551 , A61K31/5513 , C07D243/02 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/14 , C07D409/10 , C07D413/04 , C07D413/10 , C07D413/14
摘要： What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumour disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.
摘要翻译： 描述了通式（I）的BET蛋白抑制性特别是BRD4抑制性2,3-苯二氮卓类，其中R1a，R1b，R1c，R2，R3，R4，R5，A和X具有 描述，用于制备根据本发明的化合物的中间体，包含根据本发明的化合物的药物组合物及其对过度增殖性疾病，特别是肿瘤病症的预防和治疗用途。 还描述了BET蛋白抑制剂用于良性增生，动脉粥样硬化性疾病，败血症，自身免疫性疾病，血管病症，病毒感染，神经变性疾病，炎症性疾病，动脉粥样硬化性疾病和用于控制雄性生育力的用途。
-
公开(公告)号：US09890147B2
公开(公告)日：2018-02-13
申请号：US14421994
申请日：2013-08-13
发明人： Stephan Siegel , Stefan Bäurle , Arwed Cleve , Bernard Haendler , Amaury Ernesto Fernandez-Montalvan , Ursula Mönning , Sabine Krause , Pascale Lejeune , Norbert Schmees , Matthias Busemann , Simon Holton , Joachim Kuhnke
IPC分类号： A61K31/551 , C07D243/02 , C07D401/04 , C07D403/04 , C07D417/10 , C07D401/14 , C07D413/14 , C07D401/10 , C07D401/12 , C07D403/10 , C07D403/14 , C07D409/10 , C07D413/04 , C07D413/10 , A61K31/5513
CPC分类号： C07D417/10 , A61K31/551 , A61K31/5513 , C07D243/02 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D403/10 , C07D403/14 , C07D409/10 , C07D413/04 , C07D413/10 , C07D413/14
摘要： What is described are BET protein-inhibitory, in particular BRD4-inhibitory 2,3-benzodiazepines of the general formula (I) in which R1a, R1b, R1c, R2, R3, R4, R5, A and X have the meanings given in the description, intermediates for preparing the compounds according to the invention, pharmaceutical compositions comprising the compounds according to the invention and their prophylactic and therapeutic use for hyperproliferative disorders, in particular for tumor disorders. Also described is the use of BET protein inhibitors for benign hyperplasias, atherosclerotic disorders, sepsis, autoimmune disorders, vascular disorders, viral infections, for neurodegenerative disorders, for inflammatory disorders, for atherosclerotic disorders and for the control of male fertility.
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.031 秒)
